Jiangsu Recbio Technology Co Ltd

Jiangsu Recbio Technology Co., Ltd. is a vaccine company engaged in the research, development, and commercialization of subunit vaccines in the People's Republic of China. Its pipeline includes HPV vaccine candidates such as REC603, a recombinant 9-valent HPV vaccine in phase III clinical trials, and REC601 and REC602, bivalent recombinant HPV vaccines in phase I trials. The company also develops candidates for shingles, respiratory syncytial virus, human metapneumovirus, human cytomegalovirus, COVID-19, hepatitis B, herpes simplex virus, and influenza. Founded in 2011, it is headquartered in Taizhou, the People's Republic of China.